Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs

Clinical Pharmacokinetics

Volumn 51, Issue 8, 2012, Pages 481-499

  Dostalek, Miroslav ^a,b   Akhlaghi, Fatemeh ^a   Puzanovova, Martina ^c  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b CERTARA UK LIMITED   (United Kingdom)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diabetes mellitus; pharmacokinetics; pharmacology

Indexed keywords

ALBUMIN; AMPICILLIN; ANTIDIABETIC AGENT; DIAZEPAM; GLIPIZIDE; HUMAN INSULIN; INSULIN; INSULIN I 131; LIDOCAINE; LORAZEPAM; METFORMIN; METOCLOPRAMIDE; MYCOPHENOLIC ACID; OXAZEPAM; PARACETAMOL; PHENAZONE; PHENYTOIN; PIG INSULIN; PIOGLITAZONE; PROPRANOLOL; ROSIGLITAZONE; SALICYLIC ACID; SULFAFURAZOLE; TACROLIMUS; THEOPHYLLINE; TOLAZAMIDE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; XENON 133;

ADIPOSE TISSUE BLOOD FLOW; AGE; DIABETES MELLITUS; DIETARY INTAKE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; GENDER; HUMAN; KIDNEY DISEASE; MUSCLE BLOOD FLOW; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 84863449162     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11631900-000000000-00000     Document Type: Review

References (254)

1. Wild S,RoglicG,GreenA, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004May; 27 (5): 1047-53 (Pubitemid 38579764)
2. International Diabetes Federation Task Force on Diabetes Health Economy. Diabetes heath economics: facts, figures, and forecasts. Brussels: International Diabetes Federation, 1997
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 Sep; 21 (9): 1414-31 (Pubitemid 28405191)
4. Rossing P, de Zeeuw D. Need for better diabetes treatment for improved renal outcome. Kidney Int Suppl 2011 Mar; (120): S28-32
5. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults: WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 1993 Jan; 16 (1): 157-77 (Pubitemid 23013841)
6. Arslanian S. Type 2 diabetes in children: clinical aspects and risk factors. Horm Res 2002; 57 Suppl. 1: 19-28 (Pubitemid 34458077)
7. World Health Organization. Diabetes fact sheet no. 312, August 2011 [online]. Available from URL: http://www.who.int/mediacentre/factsheets [Accessed 2012 May 5]
8. Morwessel NJ. The genetic basis of diabetes mellitus. AACN Clin Issues 1998 Nov; 9 (4): 539-54
9. Herder C, Karakas M, Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther 2011 Jul; 90 (1): 52-66
10. Wing RR, Goldstein MG, Acton KJ, et al. Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care 2001 Jan; 24 (1): 117-23 (Pubitemid 32104231)
11. Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005 Sep; 99 (3): 1193-204 (Pubitemid 41214540)
12. LaMonte MJ, Blair SN, Church TS. Physical activity and diabetes prevention. J Appl Physiol 2005 Sep; 99 (3): 1205-13 (Pubitemid 41214541)
13. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004 Jun 1; 140 (11): 945-50 (Pubitemid 38685285)
14. Rendell M, Lassek WD, Ross DA, et al. A pharmaceutical profile of diabetic patients. J Chronic Dis 1983; 36 (2): 193-202 (Pubitemid 13177686)
15. Isacson D, Stalhammar J. Prescription drug use among diabetics: a population study. J Chronic Dis 1987; 40 (7): 651-60 (Pubitemid 17113471)
16. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007 [published erratum appears in Diabetes Care 2008; 31 (6): 1271].
17. Diabetes Care 2008; 31 (3): 596-615
18. Watkins P. Diabetes and its management. Oxford: Blackwell Publishing, 2003
19. Aggarwal S. What's fueling the biotech engine-2010 to 2011. Nat Biotechnol 2011; 29 (12): 1083-9
20. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991 Jun; 20 (6): 477-90
21. Cashion AK, Holmes SL, Hathaway DK, et al. Gastroparesis following kidney/pancreas transplant. Clin Transplant 2004 Jun; 18 (3): 306-11 (Pubitemid 38744856)
22. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels: implications for drug dosage regimens (part I). Clin Pharmacokinet 1990 Aug; 19 (2): 147-59 (Pubitemid 20211325)
23. Okabe N, Hashizume N. Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism. Biol Pharm Bull 1994 Jan; 17 (1): 16-21 (Pubitemid 24056977)
24. Wang T, Shankar K, Ronis MJ, et al. Mechanisms and outcomes of drug-and toxicant-induced liver toxicity in diabetes. Crit Rev Toxicol 2007 Jun; 37 (5): 413-59 (Pubitemid 47035211)
25. Zhu L. Gastric mucosal blood flow and blood viscosity in patients with diabetes [in Chinese]. Zhonghua Yi Xue Za Zhi 1993 Aug; 73 (8): 476-8, 511
26. Jacobson ED, Chang AC. Comparison of gastrin and histamine on gastric mucosal blood flow. Proc Soc Exp Biol Med 1969 Feb; 130 (2): 484-6
27. Jacobson ED, Linford RH, Grossman MI. Gastric secretion in relation to mucosal blood flow studied by a clearance technic. J Clin Invest 1966 Jan; 45 (1): 1-13
28. Moody FG. Oxygen consumption during thiocyanate inhibition of gastric acid secretion in dogs. Am J Physiol 1968 Jul; 215 (1): 127-31
29. Hasler WL, Coleski R, Chey WD, et al. Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. Am J Physiol Gastrointest Liver Physiol 2008 Jun; 294 (6): G1384-91
30. Stacher G. Diabetes mellitus and the stomach. Diabetologia 2001 Sep; 44 (9): 1080-93 (Pubitemid 32835499)
31. Samsom M, Bharucha A, Gerich JE, et al. Diabetes mellitus and gastric emptying: questions and issues in clinical practice. Diabetes Metab Res Rev 2009 Sep; 25 (6): 502-14
32. Domstad PA, Kim EE, Coupal JJ, et al. Biologic gastric emptying time in diabetic patients, using Tc-99m-labeled resin-oatmeal with and without metoclopramide. J Nucl Med 1980 Nov; 21 (11): 1098-100 (Pubitemid 10024821)
33. Horowitz M, McNeil JD, Maddern GJ, et al. Abnormalities of gastric and esophageal emptying in polymyositis and dermatomyositis. Gastroenterology 1986 Feb; 90 (2): 434-9 (Pubitemid 16136688)
34. Keshavarzian A, Iber FL, Vaeth J. Gastric emptying in patients with insulinrequiring diabetes mellitus. Am J Gastroenterol 1987 Jan; 82 (1): 29-35 (Pubitemid 17231680)
35. Gilbey SG, Watkins PJ. Measurement by epigastric impedance of gastric emptying in diabetic autonomic neuropathy. Diabet Med 1987 Mar-Apr; 4 (2): 122-6 (Pubitemid 17051638)
36. Caballero-Plasencia AM, Muros-Navarro MC, Martin-Ruiz JL, et al. Gastroparesis of digestible and indigestible solids in patients with insulindependent diabetes mellitus or functional dyspepsia. Dig Dis Sci 1994 Jul; 39 (7): 1409-15 (Pubitemid 24246428)
37. Ziegler D, Schadewaldt P, Pour Mirza A, et al. [13C]octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia 1996 Jul; 39 (7): 823-30 (Pubitemid 26228112)
38. Lipp RW, Schnedl WJ, Hammer HF, et al. Evidence of accelerated gastric emptying in longstanding diabetic patients after ingestion of a semisolid meal. J Nucl Med 1997 May; 38 (5): 814-8
39. Dutta U, Padhy AK, Ahuja V, et al. Double blind controlled trial of effect of cisapride on gastric emptying in diabetics. Trop Gastroenterol 1999 Jul-Sep; 20 (3): 116-9
40. Loo FD, Palmer DW, Soergel KH, et al. Gastric emptying in patients with diabetes mellitus. Gastroenterology 1984 Mar; 86 (3): 485-94 (Pubitemid 14154659)
41. Merio R, Festa A, Bergmann H, et al. Slow gastric emptying in type I diabetes: relation to autonomic and peripheral neuropathy, blood glucose, and glycemic control. Diabetes Care 1997 Mar; 20 (3): 419-23 (Pubitemid 27098234)
42. De Block CE, De Leeuw IH, Pelckmans PA, et al. Delayed gastric emptying and gastric autoimmunity in type 1 diabetes. Diabetes Care 2002 May; 25 (5): 912-7 (Pubitemid 41094292)
43. Meier M, Linke R, Tatsch K, et al. An advanced approach for the assessment of gastric motor function in long-term type 1 diabetes mellitus with and without autonomic neuropathy. Clin Auton Res 2002 Jun; 12 (3): 197-202 (Pubitemid 34994582)
44. Iber F, Parveen S, Vandrunen M, et al. Relation of symptoms to impaired stomach, small bowel, and colon motility in long-standing diabetes. Dig Dis Sci 1993; 38 (1): 45-50 (Pubitemid 23039451)
45. Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989 Mar; 32 (3): 151-9 (Pubitemid 19117093)
46. Wegener M, Borsch G, Schaffstein J, et al. Gastrointestinal transit disorders in patients with insulin-treated diabetes mellitus. Dig Dis 1990; 8 (1): 23-36
47. Cotroneo P, Grattagliano A, Rapaccini GL, et al. Gastric emptying rate and hormonal response in type II diabetics. Diabetes Res 1991 Jun; 17 (2): 99-104
48. Annese V, Bassotti G, Caruso N, et al. Gastrointestinal motor dysfunction, symptoms, and neuropathy in noninsulin-dependent (type 2) diabetes mellitus. J Clin Gastroenterol 1999 Sep; 29 (2): 171-7 (Pubitemid 29404466)
49. Chang CS, Kao CH, Wang YS, et al. Discrepant pattern of solid and liquid gastric emptying in Chinese patients with type II diabetes mellitus. Nucl Med Commun 1996 Jan; 17 (1): 60-5
50. Qi HB, Luo JY, Zhu YL, et al. Gastric myoelectrical activity and gastric emptying in diabetic patients with dyspeptic symptoms. World J Gastroenterol 2002 Feb; 8 (1): 180-2
51. Camilleri M. Clinical practice: diabetic gastroparesis. N Engl J Med 2007 Feb 22; 356 (8): 820-9
52. Boas I. Diseases of stomach. Leipzig: Georg Thieme, 1925
53. Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 1994 Jun; 37 (6): 543-51 (Pubitemid 24162424)
54. Horowitz M, Wishart JM, Jones KL, et al. Gastric emptying in diabetes: an overview. Diabet Med 1996 Sep; 13 (9 Suppl. 5): S16-22
55. Jones KL, Russo A, Stevens JE, et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001 Jul; 24 (7): 1264-9 (Pubitemid 33716409)
56. Kong MF, Horowitz M. Gastric emptying in diabetes mellitus: relationship to blood-glucose control. Clin Geriatr Med 1999 May; 15 (2): 321-38 (Pubitemid 29235187)
57. Chang J, Rayner C, Jones K, et al. Diabetic gastroparesis: backwards and forwards. J Gastroenterol Hepatol 2011; 26 Suppl. 1: 46-57
58. Horowitz M, O'Donovan D, Jones KL, et al. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002 Mar; 19 (3): 177-94 (Pubitemid 34429648)
59. Naesens M, Verbeke K, Vanrenterghem Y, et al. Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. Br J Clin Pharmacol 2007 May; 63 (5): 541-7 (Pubitemid 46632575)
60. Bian RW, Lou QL, Gu LB, et al. Delayed gastric emptying is related to cardiovascular autonomic neuropathy in Chinese patients with type 2 diabetes. Acta Gastroenterol Belg 2011 Mar; 74 (1): 28-33
61. Lyrenas EB, Olsson EH, Arvidsson UC, et al. Prevalence and determinants of solid and liquid gastric emptying in unstable type I diabetes: relationship to postprandial blood glucose concentrations. Diabetes Care 1997 Mar; 20 (3): 413-8 (Pubitemid 27098233)
62. Wright RA, Clemente R, Wathen R. Diabetic gastroparesis: an abnormality of gastric emptying of solids. Am J Med Sci 1985 Jun; 289 (6): 240-2 (Pubitemid 16051587)
63. Troncon LE, Rosa-e-Silva L, Oliveira RB, et al. Abnormal intragastric distribution of a liquid nutrient meal in patients with diabetes mellitus. Dig Dis Sci 1998 Jul; 43 (7): 1421-9 (Pubitemid 28357258)
64. Horowitz M, Maddox AF, Wishart JM, et al. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991; 18 (4): 229-34
65. Nowak TV, Johnson CP, Kalbfleisch JH, et al. Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut 1995 Jul; 37 (1): 23-9
66. Kong MF, King P, Macdonald IA, et al. Euglycaemic hyperinsulinaemia does not affect gastric emptying in type I and type II diabetes mellitus. Diabetologia 1999 Mar; 42 (3): 365-72 (Pubitemid 29111445)
67. Frank JW, Saslow SB, Camilleri M, et al. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995 Sep; 109 (3): 755-65
68. Schwartz JG, Green GM, Guan D, et al. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 1996 May; 19 (5): 468-71 (Pubitemid 26143749)
69. Rayner CK, Samsom M, Jones KL, et al. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001 Feb; 24 (2): 371-81 (Pubitemid 32119141)
70. MacGregor IL, Gueller R, Watts HD, et al. The effect of acute hyperglycemia on gastric emptying in man. Gastroenterology 1976 Feb; 70 (2): 190-6
71. Russo A, Stevens JE, Chen R, et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab 2005 Aug; 90 (8): 4489-95 (Pubitemid 41159331)
72. Asmar M. New physiological effects of the incretin hormones GLP-1 and GIP. Dan Med Bull 2011 Feb; 58 (2): B4248
73. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 Nov 11; 368 (9548): 1696-705 (Pubitemid 46048557)
74. Hillman M, Eriksson L, Mared L, et al. Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus. J Cyst Fibros 2012 Mar; 11 (2): 144-9
75. Kuo P, Stevens JE, Russo A, et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis: effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 2011 May; 96 (5): E851-5
76. Triantafyllou K, Kalantzis C, Papadopoulos AA, et al. Video-capsule endoscopy gastric and small bowel transit time and completeness of the examination in patients with diabetes mellitus.Dig LiverDis 2007 Jun; 39 (6): 575-80 (Pubitemid 46778162)
77. Jung HK, Kim DY, Moon IH, et al. Colonic transit time in diabetic patients: comparison with healthy subjects and the effect of autonomic neuropathy. Yonsei Med J 2003 Apr 30; 44 (2): 265-72 (Pubitemid 36592188)
78. Wu MJ, Chang CS, Cheng CH, et al. Colonic transit time in long-term dialysis patients. Am J Kidney Dis 2004 Aug; 44 (2): 322-7
79. Iida M, Ikeda M, Kishimoto M, et al. Evaluation of gut motility in type II diabetes by the radiopaque marker method. J Gastroenterol Hepatol 2000 Apr; 15 (4): 381-5 (Pubitemid 30262204)
80. Werth B, Meyer-Wyss B, Spinas GA, et al. Non-invasive assessment of gastrointestinal motility disorders in diabetic patients with and without cardiovascular signs of autonomic neuropathy. Gut 1992 Sep; 33 (9): 1199-203
81. Scarpello JH, Greaves M, Sladen GE. Small intestinal transit in diabetics. Br Med J 1976 Nov 20; 2 (6046): 1225-6
82. Dooley CP, el Newihi HM, Zeidler A, et al. Abnormalities of the migrating motor complex in diabetics with autonomic neuropathy and diarrhea. Scand J Gastroenterol 1988 Mar; 23 (2): 217-23 (Pubitemid 18096836)
83. Oliveira RB, Troncon LE, Meneghelli UG, et al. Gastric accommodation to distension and early gastric emptying in diabetics with neuropathy. Braz J Med Biol Res 1984; 17 (1): 49-53
84. Fraser RJ, Horowitz M, Maddox AF, et al. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990 Nov; 33 (11): 675-80 (Pubitemid 20377931)
85. Jebbink RJ, Samsom M, Bruijs PP, et al. Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type I diabetes mellitus. Gastroenterology 1994 Nov; 107 (5): 1390-7 (Pubitemid 24328276)
86. Della-Coletta A, Eller M. The bioavailability of tolazamid in diabetic patients and healthy subjects [abstract no. PP 1301]. Pharmacol Res 1988; 5: S174
87. Adithan C, Danda D, Shashindran CH, et al. Differential effect of type I and type II diabetes mellitus on antipyrine elimination. Methods Find Exp Clin Pharmacol 1989 Dec; 11 (12): 755-8 (Pubitemid 20101987)
88. O'Connell ME, Awni WM, Goodman M, et al. Bioavailability and disposition of metoclopramide after single-and multiple-dose administration in diabetic patients with gastroparesis. J Clin Pharmacol 1987 Aug; 27 (8): 610-4 (Pubitemid 17136256)
89. Wahlin-Boll E, Almer LO, Melander A. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. Clin Pharmacokinet 1982 Jul-Aug; 7 (4): 363-72 (Pubitemid 12020225)
90. Fuccella LM, Tamassia V, Valzelli G. Metabolism and kinetics of the hypoglycemic agent glipizide in man: comparison with glibenclamide. J Clin Pharmacol New Drugs 1973 Feb-Mar; 13 (2): 68-75
91. Stacher G, Lenglinger J, Bergmann H, et al. Gastric emptying: a contributory factor in gastro-oesophageal reflux activity? Gut 2000 Nov; 47 (5): 661-6
92. Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003 Feb; 98 (2): 259-63 (Pubitemid 36232369)
93. Havelund T, Oster-Jorgensen E, Eshoj O, et al. Effects of cisapride on gastroparesis in patients with insulin-dependent diabetes mellitus: a doubleblind controlled trial. Acta Med Scand 1987; 222 (4): 339-43 (Pubitemid 18049115)
94. de Caestecker JS, Ewing DJ, Tothill P, et al. Evaluation of oral cisapride and metoclopramide in diabetic autonomic neuropathy: an eight-week doubleblind crossover study. Aliment Pharmacol Ther 1989 Feb; 3 (1): 69-81 (Pubitemid 20118785)
95. Camilleri M, Malagelada JR, Abell TL, et al. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989 Mar; 96 (3): 704-12 (Pubitemid 19057591)
96. Nosadini R, De Kreutzenberg S, Duner E, et al. Porcine and human insulin absorption from subcutaneous tissues in normal and insulin-dependent diabetic subjects: a deconvolution-based approach. J Clin Endocrinol Metab 1988; 67 (3): 551-9
97. Moore EW, Mitchell ML, Chalmers TC. Variability in absorption of insulin-I 131 in normal and diabetic subjects after subcutaneous and intramuscular injection. J Clin Invest 1959 Jul; 38 (7): 1222-7
98. Leinonen H, Matikainen E, Juntunen J. Permeability and morphology of skeletal muscle capillaries in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1982 Mar; 22 (3): 158-62 (Pubitemid 12183671)
99. Weinstein L, Meade RH. Absorption and excretion of penicillin injected into the muscles of patients with diabetes mellitus. Nature 1961 Dec 9; 192: 987-8
100. Hildebrandt P, Sestoft L, Nielsen SL. The absorption of subcutaneously injected short-acting soluble insulin: influence of injection technique and concentration. Diabetes Care 1983 Sep-Oct; 6 (5): 459-62 (Pubitemid 13005552)
101. Sestoft L, Volund A, Gammeltoft S, et al. The biological properties of human insulin: subcutaneous absorption, receptor binding and the clinical effect in diabetics assessed by a new statistical method. Acta Med Scand 1982; 212 (1-2): 21-8 (Pubitemid 12054712)
102. Kolendorf K, Bojsen J, Nielsen SL. Adipose tissue blood flow and insulin disappearance from subcutaneous tissue. Clin Pharmacol Ther 1979 May; 25 (5 Pt 1): 598-604 (Pubitemid 9208918)
103. Lauritzen T, Binder C, Faber OK. Importance of insulin absorption, subcutaneous blood flow, and residual beta-cell function in insulin therapy. Acta Paediatr Scand Suppl 1980; 283: 81-5 (Pubitemid 11220671)
104. Haggendal E, Steen B, Svanborg A. Blood flow in subcutaneous fat tissue in patients with diabetesmellitus.ActaMed Scand 1970 Jan-Feb; 187 (1-2): 49-53
105. Dimitriadis G, Lambadiari V, Mitrou P, et al. Impaired postprandial blood flow in adipose tissue may be an early marker of insulin resistance in type 2 diabetes. Diabetes Care 2007 Dec; 30 (12): 3128-30 (Pubitemid 350255263)
106. Coppack SW, Evans RD, Fisher RM, et al. Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism 1992 Mar; 41 (3): 264-72
107. Blaak EE, Van Baak MA, Kemerink GJ, et al. Beta-adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reducedobese subjects. Metabolism 1995 Feb; 44 (2): 183-7
108. Summers LK, Samra JS, Humphreys SM, et al. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 1996 Dec; 91 (6): 679-83 (Pubitemid 26413821)
109. Jansson PA, Larsson A, Lonnroth PN. Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without noninsulin-dependent diabetes mellitus. Eur J Clin Invest 1998 Oct; 28 (10): 813-8 (Pubitemid 28488114)
110. Karpe F, Fielding BA, Ilic V, et al. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 2002 Aug; 51 (8): 2467-73 (Pubitemid 34827395)
111. Regensteiner JG, Popylisen S, Bauer TA, et al. Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med 2003; 8 (3): 169-75 (Pubitemid 38220194)
112. Kingwell BA, Formosa M, Muhlmann M, et al. Type 2 diabetic individuals have impaired leg blood flow responses to exercise: role of endotheliumdependent vasodilation. Diabetes Care 2003 Mar; 26 (3): 899-904 (Pubitemid 36929362)
113. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endotheliumdependent and independent vasodilation in patients with type 2 (non-insulindependent) diabetes mellitus. Diabetologia 1992 Aug; 35 (8): 771-6
114. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996 Mar 1; 27 (3): 567-74 (Pubitemid 26081917)
115. Schneider JG, Tilly N, Hierl T, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens 2002 Nov; 15 (11): 967-72 (Pubitemid 35217402)
116. Marin P, Andersson B, Krotkiewski M, et al. Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care 1994 May; 17 (5): 382-6 (Pubitemid 24145211)
117. Mathieu-Costello O, KongA, Ciaraldi TP, et al. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metabolism 2003 May; 52 (5): 540-6 (Pubitemid 36896278)
118. Ritov VB, Menshikova EV, He J, et al. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 2005 Jan; 54 (1): 8-14 (Pubitemid 40105089)
119. Kelley DE, He J, Menshikova EV, et al. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002 Oct; 51 (10): 2944-50
120. Yee GC, Evans WE. Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides. Pharmacotherapy 1981 Jul-Aug; 1 (1): 55-75 (Pubitemid 12015660)
121. Lerner PI, Weinstein L. Abnormalities of absorption of benzylpenicillin G and sulfisoxazole in patients with diabetes mellitus. Am J Med Sci 1964 Jul; 248: 37-51
122. Bonadonna RC, Groop L, Kraemer N, et al. Obesity and insulin resistance in humans: a dose-response study. Metabolism 1990 May; 39 (5): 452-9 (Pubitemid 20156310)
123. Rexrode KM, Manson JE, Hennekens CH. Obesity and cardiovascular disease. Curr Opin Cardiol 1996 Sep; 11 (5): 490-5 (Pubitemid 26320988)
124. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49 (2): 71-87
125. Benedek IH, Fiske 3rd WD, Griffen WO, et al. Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol 1983 Dec; 16 (6): 751-4 (Pubitemid 14208224)
126. Abernethy DR, Greenblatt DJ. Drug disposition in obese humans: an update. Clin Pharmacokinet 1986 May-Jun; 11 (3): 199-213 (Pubitemid 16079739)
127. Abernethy DR, Greenblatt DJ, Divoll M, et al. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 1983 Jun; 101 (6): 873-80 (Pubitemid 13100682)
128. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev 2008 Apr; 88 (2): 389-419 (Pubitemid 351520084)
129. Cohen MP, Ziyadeh FN, Chen S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med 2006 May; 147 (5): 211-9 (Pubitemid 43668486)
130. Day JF, Thorpe SR, Baynes JW. Nonenzymatically glucosylated albumin: in vitro preparation and isolation from normal human serum. J Biol Chem 1979 Feb 10; 254 (3): 595-7 (Pubitemid 9145923)
131. Adithan C, Danda D, Swaminathan RP, et al. Effect of diabetes mellitus on salivary paracetamol elimination. Clin Exp Pharmacol Physiol 1988 Jun; 15 (6): 465-71
132. Daintith H, Stevenson IH, O'Malley K. Influence of diabetes mellitus on drug metabolism in man. Int J Clin Pharmacol Biopharm 1976 Jan; 13 (1): 55-8
133. Salmela PI, Sotaniemi EA, Pelkonen RO. The evaluation of the drugmetabolizing capacity in patients with diabetes mellitus. Diabetes 1980 Oct; 29 (10): 788-94 (Pubitemid 12233889)
134. Murali KV, Adithan C, Shashindran CH, et al. Antipyrine metabolism in patients with diabetes mellitus. Clin Exp Pharmacol Physiol 1983 Jan-Feb; 10 (1): 7-13 (Pubitemid 13187438)
135. Pirttiaho HI, Salmela PI, Sotaniemi EA, et al. Drug metabolism in diabetic subjects with fatty livers. Br J Clin Pharmacol 1984 Dec; 18 (6): 895-9 (Pubitemid 15190527)
136. Narang AP, Dutta DV, Khare AK. Impairment of drug clearance in patients with diabetes mellitus & liver cirrhosis. Indian J Med Res 1987 Mar; 85: 321-5
137. Zysset T, Wietholtz H. Differential effect of type I and type II diabetes on antipyrine disposition in man. Eur J Clin Pharmacol 1988; 34 (4): 369-75
138. Ruiz-Cabello F, Erill S. Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 1984 Nov; 36 (5): 691-5 (Pubitemid 15224675)
139. Worner W, Preissner A, Rietbrock N. Drug-protein binding kinetics in patients with type I diabetes. Eur J Clin Pharmacol 1992; 43 (1): 97-100
140. Kearns GL, Kemp SF, Turley CP, et al. Protein binding of phenytoin and lidocaine in pediatric patients with type I diabetes mellitus. Dev Pharmacol Ther 1988; 11 (1): 14-23 (Pubitemid 18079443)
141. Kemp SF, Kearns GL, Turley CP. Alteration of phenytoin binding by glycosylation of albumin in IDDM. Diabetes 1987 Apr; 36 (4): 505-9 (Pubitemid 18023196)
142. Trovik TS, Jaeger R, JordeR, et al. Plasma protein binding of catecholamines, prazosin and propranolol in diabetes mellitus. Eur J Clin Pharmacol 1992; 43 (3): 265-8
143. Trovik TS, Jaeger R, Jorde R, et al. Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness. Br J Clin Pharmacol 1994 Nov; 38 (5): 427-32 (Pubitemid 24344030)
144. Reidenberg MM, Drayer DE. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984 Jan; 9 Suppl. 1: 18-26 (Pubitemid 14179497)
145. Keller F, Maiga M, Neumayer HH, et al. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet 1984 Jul-Sep; 9 (3): 275-82 (Pubitemid 15202289)
146. Gatti G, Crema F, Attardo-Parrinello G, et al. Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. Ther Drug Monit 1987 Dec; 9 (4): 389-91 (Pubitemid 18007758)
147. McNamara PJ, Blouin RA, Brazzell RK. The protein binding of phenytoin, propranolol, diazepam, and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm Res 1988 May; 5 (5): 261-5
148. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (part II). Clin Pharmacokinet 1990 Sep; 19 (3): 218-29 (Pubitemid 20281451)
149. Chase HP, Glasgow AM. Juvenile diabetes mellitus and serum lipids and lipoprotein levels. Am J Dis Child 1976 Oct; 130 (10): 1113-7
150. Fraze E, Donner CC, Swislocki AL, et al. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab 1985 Nov; 61 (5): 807-11 (Pubitemid 16218472)
151. Grainger-Rousseau T, McElnay J, Collier P. The influence of disease on plasma protein binding of drugs. Int J Pharmacol 1989; 54: 1-13 (Pubitemid 19198395)
152. O'Byrne S, Barry MG, Collins WC, et al. Plasma protein binding of lidocaine and warfarin in insulin-dependent and non-insulin-dependent diabetes mellitus. Clin Pharmacokinet 1993 Feb; 24 (2): 183-6 (Pubitemid 23052201)
153. Stafford WL. Abnormality in the binding of an organic anion by diabetic serum. Lancet 1962 Feb 3; 1 (7223): 243-5
154. Saadeh S. Nonalcoholic Fatty liver disease and obesity. Nutr Clin Pract 2007 Feb; 22 (1): 1-10 (Pubitemid 46175466)
155. Ijaz S, Yang W, Winslet MC, et al. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003 Dec; 10 (6): 447-56 (Pubitemid 39004270)
156. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999 Jan; 37 (1): 8-19 (Pubitemid 29043392)
157. Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. Clin Pharmacokinet 1982 Mar-Apr; 7 (2): 108-24 (Pubitemid 12070477)
158. Petrides AS, Vogt C, Schulze-Berge D, et al. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994 Mar; 19 (3): 616-27 (Pubitemid 24066891)
159. Katbamma B, Petrelli M, McCullough A. The liver in diabetes mellitus and hyperlipidemia. In: Gitlin N, editor. The liver and the systemic disease. New York: Churchill Livingstone, 1997: 73-113
160. Wang T, Fontenot RD, Soni MG, et al. Enhanced hepatotoxicity and toxic outcome of thioacetamide in streptozotocin-induced diabetic rats. Toxicol Appl Pharmacol 2000 Jul 15; 166 (2): 92-100 (Pubitemid 30497432)
161. Watkins 3rd JB, Sherman SE. Long-term diabetes alters the hepatobiliary clearance of acetaminophen, bilirubin and digoxin. J Pharmacol Exp Ther 1992 Mar; 260 (3): 1337-43
162. Shankar K, Vaidya VS, Apte UM, et al. Type 1 diabetic mice are protected from acetaminophen hepatotoxicity. Toxicol Sci 2003 Jun; 73 (2): 220-34 (Pubitemid 36701729)
163. Lee JH, Yang SH, Oh JM, et al. Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozotocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol 2010; 62 (1): 1-23
164. Cheng PY, Morgan ET. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2001 Jun; 2 (2): 165-83 (Pubitemid 32544553)
165. Sotaniemi EA, Pelkonen O, Arranto AJ, et al. Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol 2002 Mar; 90 (3): 155-60 (Pubitemid 34289614)
166. Lucas D, Farez C, Bardou LG, et al. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 1998; 12 (5): 553-8 (Pubitemid 29166500)
167. Wang Z, Hall SD, Maya JF, et al. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 2003 Jan; 55 (1): 77-85 (Pubitemid 36110842)
168. Hannon-Fletcher MP, O'Kane MJ, Moles KW, et al. Lymphocyte cytochrome
169. Haufroid V, Ligocka D, Buysschaert M, et al. Cytochrome P4502E1 (CYP2E1) expression in peripheral blood lymphocytes: evaluation in hepatitis C and diabetes. Eur J Clin Pharmacol 2003 May; 59 (1): 29-33 (Pubitemid 36702756)
170. Song BJ, Veech RL, Saenger P. Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. J Clin Endocrinol Metab 1990 Oct; 71 (4): 1036-40
171. Pucci L, Chirulli V, Marini S, et al. Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals. Pharmacol Res 2005 Jun; 51 (6): 561-5
172. Adithan C, Sriram G, Swaminathan RP, et al. Effect of type II diabetes mellitus on theophylline elimination. Int J Clin Pharmacol Ther Toxicol 1989 May; 27 (5): 258-60 (Pubitemid 19128613)
173. Zysset T, Wietholtz H. Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus. Eur J Clin Pharmacol 1991; 41 (5): 449-52
174. Matzke GR, Frye RF, Early JJ, et al. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 2000 Feb; 20 (2): 182-90 (Pubitemid 30073838)
175. Korrapati MR, Vestal RE, Loi CM. Theophylline metabolism in healthy nonsmokers and in patients with insulin-dependent diabetes mellitus. Clin Pharmacol Ther 1995 Apr; 57 (4): 413-8
176. Ueda H, Sakurai T, Ota M, et al. Disappearance rate of tolbutamide in normal subjects and in diabetes mellitus, liver cirrhosis, and renal disease. Diabetes 1963 Sep-Oct; 12: 414-9
177. Dyer JR, Davis TM, Giele C, et al. The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly. Br J Clin Pharmacol 1994 Sep; 38 (3): 205-12 (Pubitemid 24282740)
178. Dostalek M, Court MH, Yan B, et al. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol 2011 Jul; 163 (5): 937-47
179. Marques MP, Coelho EB, Dos Santos NA, et al. Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. Eur J Clin Pharmacol 2002 Dec; 58 (9): 607-14 (Pubitemid 35478187)
180. Moises EC, Duarte Lde B, Cavalli Rde C, et al. Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. Eur J Clin Pharmacol 2008 Dec; 64 (12): 1189-96
181. McRobie DJ, Glover DD, Tracy TS. Effects of gestational and overt diabetes on human placental cytochromes P450 and glutathione S-transferase. Drug Metab Dispos 1998 Apr; 26 (4): 367-71 (Pubitemid 28201248)
182. McRobie DJ, Korzekwa KR, Glover DD, et al. The effects of diabetes on placental aromatase activity. J Steroid Biochem Mol Biol 1997 Sep-Oct; 63 (1-3): 147-53 (Pubitemid 28018147)
183. Juan D, Molitch ME, Johnson MK, et al. Unaltered drug metabolizing enzyme systems in type II diabetes mellitus before and during glyburide therapy. J Clin Pharmacol 1990 Oct; 30 (10): 943-7 (Pubitemid 20353560)
184. West IC. Radicals and oxidative stress in diabetes. Diabet Med 2000 Mar; 17 (3): 171-80 (Pubitemid 30212288)
185. Atalay M, Laaksonen DE, Niskanen L, et al. Altered antioxidant enzyme defences in insulin-dependent diabetic men with increased resting and exercise-induced oxidative stress. Acta Physiol Scand 1997 Oct; 161 (2): 195-201 (Pubitemid 27445703)
186. Dincer Y, Alademir Z, Ilkova H, et al. Susceptibility of glutatione and glutathione-related antioxidant activity to hydrogen peroxide in patients with type 2 diabetes: effect of glycemic control. Clin Biochem 2002 Jun; 35 (4): 297-301 (Pubitemid 34804900)
187. Graber R, Farine JC, Fumagalli I, et al. Apoptosis and oxidative status in peripheral blood mononuclear cells of diabetic patients. Apoptosis 1999 Aug; 4 (4): 263-70 (Pubitemid 29424489)
188. Sailaja YR, Baskar R, Saralakumari D. The antioxidant status during maturation of reticulocytes to erythrocytes in type 2 diabetics. Free Radic Biol Med 2003 Jul 15; 35 (2): 133-9 (Pubitemid 36835913)
189. Albrecht C, Simon-Vermot I, Elliott JI, et al. Leukocyte ABCA1 gene expression is associated with fasting glucose concentration in normoglycemic men. Metabolism 2004 Jan; 53 (1): 17-21 (Pubitemid 38071930)
190. Zhou H, Tan KC, Shiu SW, et al. Determinants of leukocyte adenosine triphosphate-binding cassette transporter G1 gene expression in type 2 diabetes mellitus. Metabolism 2008 Aug; 57 (8): 1135-40 (Pubitemid 351978072)
191. Mauldin JP, NagelinMH,Wojcik AJ, et al. Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetesmellitus.Circulation 2008 May 27; 117 (21): 2785-92 (Pubitemid 351770459)
192. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999 Jan; 88 (1): 1-7 (Pubitemid 29037361)
193. Suzuki Y, Arakawa M. The treatment of the uraemic diabetic. Are we doing enough?Aview from Japan. Fumitake Gejyo and Collaborate Study Group. Nephrol Dial Transplant 1995; 10 Suppl. 7: 47-55
194. Raine AE. The rising tide of diabetic nephropathy: the warning before the flood? Nephrol Dial Transplant 1995; 10 (4): 460-1
195. Andersen AR, Christiansen JS, Andersen JK, et al. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983 Dec; 25 (6): 496-501 (Pubitemid 14200886)
196. Sasso FC, De Nicola L, Carbonara O, et al. Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care 2006 Mar; 29 (3): 498-503 (Pubitemid 44115343)
197. Hasslacher C, Kempe HP, Bostedt-Kiesel A. ACE inhibitors and diabetic nephropathy: clinical and experimental findings. Clin Investig 1993; 71 (5 Suppl.): S20-4 (Pubitemid 23137525)
198. Ebihara I, Nakamura T, Shimada N, et al. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in noninsulin-dependent diabetes mellitus.AmJ Kidney Dis 1998 Oct; 32 (4): 544-50 (Pubitemid 28477698)
199. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study.Arch InternMed 1996 Feb 12; 156 (3): 286-9 (Pubitemid 26058479)
200. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997 Oct; 20 (10): 1576-81 (Pubitemid 27415037)
201. Gill GV, Hardy KJ, Patrick AW, et al. Random blood glucose estimation in type 2 diabetes: does it reflect overall glycaemic control? Diabet Med 1994 Aug-Sep; 11 (7): 705-8 (Pubitemid 24257118)
202. Meeme A, Kasozi H. Effect of glycaemic control on glomerular filtration rate in diabetes mellitus patients. Afr Health Sci 2009 Aug 1; 9 Suppl. 1: S23-6
203. Maurer AC. The therapy of diabetes. Am Sci 1979 Jul-Aug; 67 (4): 422-31 (Pubitemid 9233705)
204. Madacsy L, Bokor M, Matusovits L. Penicillin clearance in diabetic children. Acta Paediatr Acad Sci Hung 1975; 16 (2): 139-42
205. Garcia G, de Vidal EL, Trujillo H. Serum levels and urinary concentrations of kanamicin, bekanamicin and amikacin (BB-K8) in diabetic children and a control group. J Int Med Res 1977; 5 (5): 322-9 (Pubitemid 8164062)
206. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004 Dec 1; 292 (21): 2585-90 (Pubitemid 39577514)
207. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21-27; 364 (9435): 685-96 (Pubitemid 39140624)
208. Skottheim IB, Gedde-Dahl A, Hejazifar S, et al. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci 2008 Apr 23; 33 (4-5): 317-25
209. Berlin I, Grimaldi A, Bosquet F, et al. Decreased beta-adrenergic sensitivity in insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1986 Jul; 63 (1): 262-5 (Pubitemid 16093043)
210. Lloyd-Mostyn RH, Watkins PJ. Defective innervation of heart in diabetic autonomic neuropathy. Br Med J 1975 Jul 5; 3 (5974): 15-7
211. Berlin I, Grimaldi A, Landault C, et al. Lack of hypoglycemic symptoms and decreased beta-adrenergic sensitivity in insulin-dependent diabetic patients. J Clin Endocrinol Metab 1988 Feb; 66 (2): 273-8 (Pubitemid 18065167)
212. Berlin I, Grimaldi A, Payan C, et al. Hypoglycemic symptoms and decreased beta-adrenergic sensitivity in insulin-dependent diabetic patients. Diabetes Care 1987 Nov-Dec; 10 (6): 742-7 (Pubitemid 18049831)
213. Lynch C, Exton J. Alterations in G-protein-mediated cell signaling in diabetes mellitus. In: Milligan G, Wakelam M, editors. G-proteins: signal transduction and disease. London: Academic Press Limited, 1992: 87-108
214. Terada M, Yasuda H, Kashawagi A, et al. Sympathetic nerve dysfunction and increased heart rate response to epinephrine in diabetic patients. Amsterdam: Elsevier Science Publishers, 1987
215. Packer M, Lee WH, Medina N, et al. Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. Am J Med 1987 Jun; 82 (6): 1119-26
216. Self TH, Hood J, Miller ST. Diabetes mellitus and the hypoprothrombinemic response to warfarin [letter]. JAMA 1978 May 26; 239 (21): 2239 (Pubitemid 8340938)
217. Lansang MC, Ma L, Schold JD, et al. The relationship between diabetes and infectious hospitalizations in renal transplant recipients. Diabetes Care 2006 Jul; 29 (7): 1659-60 (Pubitemid 44127598)
218. First MR. Posttransplant diabetes mellitus [letter]. Transplantation 2003 May 27; 75 (10): 1769
219. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States.AmJ Transplant 2003 Feb; 3 (2): 178-85 (Pubitemid 36323115)
220. Ye X, Kuo HT, Sampaio MS, et al. Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. Clin Transplant 2011; 25 (6): 885-91
221. Mendonza AE, Gohh RY, Akhlaghi F. Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. Clin Pharmacokinet 2008; 47 (11): 733-42
222. Akhlaghi F, Dostalek M, Falck P, et al. The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus. Ther Drug Monit 2012; 34 (1): 38-45
223. Mendonza AE, Zahir H, Gohh RY, et al. Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2007 Aug; 29 (4): 391-8 (Pubitemid 47220454)
224. Van Duijnhoven E, Christiaans M, Undre N, et al. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. Transplant Proc 1998 Jun; 30 (4): 1268-70 (Pubitemid 28309567)
225. Akhlaghi F, Patel CG, Zuniga XP, et al. Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit 2006 Feb; 28 (1): 95-101 (Pubitemid 44391701)
226. Van Hest RM, Mathot RA, Vulto AG, et al. Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2004 Dec; 26 (6): 620-5 (Pubitemid 39579142)
227. Pescovitz MD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003 Dec; 3 (12): 1581-6 (Pubitemid 37541517)
228. Akhlaghi F, Dostalek M, Mendonza AE, et al. Reduced levels of biomarkers of immunosuppressive activity in diabetic kidney transplant recipients [poster no. P204]. International Association of Therapeutic Drug Monitoring and Clinical Toxicology; 2011 Oct 2-6; Stuttgart, Germany
229. Akhlaghi F, Chitnis SD, Ionita I, et al. Impact of diabetes mellitus on metabolism of immunosuppressive agents: cyclosporin, tacrolimus and prednisone [poster no. P201]. International Association of Therapeutic Drug Monitoring and Clinical Toxicology; 2011 Oct 2-6; Stuttgart, Germany
230. Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 2001 Jun; 24 (6): 1044-9 (Pubitemid 33716374)
231. Alba-Loureiro TC, Munhoz CD, Martins JO, et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res 2007 Aug; 40 (8): 1037-44 (Pubitemid 47232857)
232. Jolin T, Tarin MJ, Garcia MD. Induction of goitre by PTU or KCIO4 in male and female rats: effect of gonadectomy. Acta Endocrinol (Copenh) 1973 Sep; 74 (1): 88-104
233. Garcia-Leme J, Bohm GM, Migliorini RH, et al. Possible participation of insulin in the control of vascular permeability. Eur J Pharmacol 1974 Dec; 29 (2): 298-306
234. Llorach MA, Bohm GM, Leme JG. Decreased vascular reactions to permeability factors in experimental diabetes. Br J Exp Pathol 1976 Dec; 57 (6): 747-54 (Pubitemid 8015242)
235. Fortes ZB, Garcia Leme J, Scivoletto R. Vascular reactivity in diabetes mellitus: role of the endothelial cell. Br J Pharmacol 1983 Jul; 79 (3): 771-81
236. Fortes ZB, Garcia Leme J, Scivoletto R. Vascular reactivity in diabetes mellitus: possible role of insulin on the endothelial cell. Br J Pharmacol 1984 Nov; 83 (3): 635-43 (Pubitemid 15222076)
237. Cavalher-Machado SC, de Lima WT, Damazo AS, et al. Down-regulation of mast cell activation and airway reactivity in diabetic rats: role of insulin. Eur Respir J 2004 Oct; 24 (4): 552-8 (Pubitemid 39406127)
238. Sannomiya P, Pereira MA, Garcia-Leme J. Inhibition of leukocyte chemotaxis by serum factor in diabetes mellitus: selective depression of cell responses mediated by complement-derived chemoattractants. Agents Actions 1990 Jun; 30 (3-4): 369-76 (Pubitemid 20185147)
239. Sannomiya P, Oliveira MA, Fortes ZB. Aminoguanidine and the prevention of leukocyte dysfunction in diabetes mellitus: a direct vital microscopic study. Br J Pharmacol 1997 Nov; 122 (5): 894-8 (Pubitemid 27460171)
240. Fortes ZB, Farsky SP, Oliveira MA, et al. Direct vital microscopic study of defective leukocyte-endothelial interaction in diabetes mellitus. Diabetes 1991 Oct; 40 (10): 1267-73
241. Cruz JW, Oliveira MA, Hohman TC, et al. Influence of tolrestat on the defective leukocyte-endothelial interaction in experimental diabetes. Eur J Pharmacol 2000 Mar 10; 391 (1-2): 163-74 (Pubitemid 30138093)
242. Zanardo RC, Cruz JW, Martinez LL, et al. Probucol restores the defective leukocyte-endothelial interaction in experimental diabetes. Eur J Pharmacol 2003 Oct 8; 478 (2-3): 211-9 (Pubitemid 37315741)
243. Anjos-Valotta EA, Martins JO, Oliveira MA, et al. Inhibition of tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 expression in diabetic rats: role of insulin. Inflamm Res 2006 Jan; 55 (1): 16-22 (Pubitemid 43142807)
244. Moriguchi P, Sannomiya P, Lara PF, et al. Lymphatic system changes in diabetes mellitus: role of insulin and hyperglycemia. Diabetes Metab Res Rev 2005; 21 (2): 150-7 (Pubitemid 40467661)
245. Boichot E, Sannomiya P, Escofier N, et al. Endotoxin-induced acute lung injury in rats: role of insulin. Pulm Pharmacol Ther 1999; 12 (5): 285-90 (Pubitemid 29527919)
246. Shaw LM, Figurski M, Milone MC, et al. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol 2007 Sep; 2 (5): 1062-72
247. Patel CG, Richman K, Yang D, et al. Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. Ther DrugMonit 2007 Dec; 29 (6): 735-42 (Pubitemid 350190849)
248. Jain J, Almquist SJ, Ford PJ, et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol 2004 Feb 15; 67 (4): 767-76 (Pubitemid 38125261)
249. Fulton B, Markham A. Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996 Feb; 51 (2): 278-98
250. Abbott KC, Hypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001 Dec; 3 (4): 203-11 (Pubitemid 34051921)
251. Dharnidharka VR, Agodoa LY, Abbott KC. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients: an analysis of USRDS data. Am J Transplant 2007 Mar; 7 (3): 653-61 (Pubitemid 46376457)
252. Redman DR, Prescott LF. Failure of induction of liver microsomal enzymes by tolbutamide in maturity-onset diabetics. Diabetes 1973 Mar; 22 (3): 210-1
253. Sambol NC, Chiang J, O'Conner M, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulindependent diabetes mellitus. J Clin Pharmacol 1996 Nov; 36 (11): 1012-21 (Pubitemid 27014728)
254. Plosker GL, Figgitt DP. Repaglinide: a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics 2004; 22 (6): 389-411 (Pubitemid 38609815)